Pathophysiological Protein Corona Governs the Biological Fate of Nanoparticles
- ACS Appl Mater Interfaces. 2026 Apr 22;18(15):21500-21513. doi: 10.1021/acsami.5c23016.
- 1. Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- 2. Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao 266237, China.
- 3. Department of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
- 4. The First Department of Breast Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Medical Group), Qingdao 266042, China.
- 5. Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao 266042, China.
Protein corona fundamentally redefines the biological identity, cellular interactions, and in vivo fate of nanoparticles. Disease-induced alterations in blood composition generate pathological corona profiles; however, the impact of disease-mediated corona remodeling on the biological effects of nanoparticles remains poorly understood. Here, we systematically characterized the protein coronas and biological responses of surface-engineered polystyrene nanoparticles incubated with sera from healthy donors and patients with nonsmall cell lung Cancer (NSCLC). Our findings show that disease status and nanoparticle surface chemistry jointly reprogram corona composition, leading to marked alterations in immune recognition and pharmacokinetic profiles. Specifically, NSCLC-derived coronas were enriched in complement proteins, resulting in pronounced complement activation and enhanced macrophage-mediated clearance, while attenuating systemic circulation of nanoparticles. These findings elucidate the critical role of disease-specific protein coronas in modulating nanobio interactions and underscore the necessity of accounting for pathological environments in the rational design and clinical translation of nanomedicines.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
-
-
-
Research Areas: Metabolic Disease
-